Please assess the completion status of the following clinical trial:

Trial Title: Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* Symptom onset less than 24 hrs prior to diagnostic CT scan~* Spontaneous ICH less than or equal to 30 cc or primary IVH~* IVH obstructing 3rd and/or 4th ventricles~* ICH clot stability at 6 hours or more post IVC placement~* IVH clot stability at 6 hours or more post IVC placement~* Catheter tract bleeding stability 6 hours or more post IVC placement~* EVD placed per standard medical care~* SBP less than 200 mmHg sustained for 6 hours prior to drug administration~* Able to randomize within 72 hours of diagnostic CT scan~* Historical Rankin of 0 or 1~Exclusion Criteria:~* Suspected or untreated ruptured cerebral aneurysm, AVM, or tumor~* Presence of a choroid plexus vascular malformation or Moyamoya~* Clotting disorders~* Platelet count less than 100,000, INR greater than 1.4~* Pregnancy~* Infratentorial hemorrhage~* SAH at clinical presentation~* ICH/IVH enlargement that cannot be stabilized in the treatment time window~* Ongoing internal bleeding~* Superficial or surface bleeding~* Prior enrollment in the study~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Planned or simultaneous participation (between screening and Day-30) in another interventional medical investigation or clinical trial.~* No subject or legal representative to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Alteplase (Type: EXPERIMENTAL): administration of alteplase via the intraventricular catheter
- Saline Placebo (Type: PLACEBO_COMPARATOR): 1 ml of normal saline administered via the intraventricular catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).